Cargando…

Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study

We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC). Plasma‐free DNA, germline DNA, and tissue DNA were isolated from 41 patients with HCC. Serial ctDNAs were analyzed by...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Gui‐Qi, Liu, Wei‐Ren, Tang, Zheng, Qu, Wei‐Feng, Fang, Yuan, Jiang, Xi‐Fei, Song, Shu‐Shu, Wang, Han, Tao, Chen‐Yang, Zhou, Pei‐Yun, Huang, Run, Gao, Jun, Sun, Hai‐Xiang, Ding, Zhen‐Bin, Peng, Yuan‐Fei, Dai, Zhi, Zhou, Jian, Fan, Jia, Shi, Ying‐Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763657/
https://www.ncbi.nlm.nih.gov/pubmed/34543520
http://dx.doi.org/10.1002/1878-0261.13105
_version_ 1784633995823153152
author Zhu, Gui‐Qi
Liu, Wei‐Ren
Tang, Zheng
Qu, Wei‐Feng
Fang, Yuan
Jiang, Xi‐Fei
Song, Shu‐Shu
Wang, Han
Tao, Chen‐Yang
Zhou, Pei‐Yun
Huang, Run
Gao, Jun
Sun, Hai‐Xiang
Ding, Zhen‐Bin
Peng, Yuan‐Fei
Dai, Zhi
Zhou, Jian
Fan, Jia
Shi, Ying‐Hong
author_facet Zhu, Gui‐Qi
Liu, Wei‐Ren
Tang, Zheng
Qu, Wei‐Feng
Fang, Yuan
Jiang, Xi‐Fei
Song, Shu‐Shu
Wang, Han
Tao, Chen‐Yang
Zhou, Pei‐Yun
Huang, Run
Gao, Jun
Sun, Hai‐Xiang
Ding, Zhen‐Bin
Peng, Yuan‐Fei
Dai, Zhi
Zhou, Jian
Fan, Jia
Shi, Ying‐Hong
author_sort Zhu, Gui‐Qi
collection PubMed
description We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC). Plasma‐free DNA, germline DNA, and tissue DNA were isolated from 41 patients with HCC. Serial ctDNAs were analyzed by next‐generation sequencing before and after operation. Whole‐exome sequencing was used to detect the DNA of HCC and adjacent tissues. In total, 47 gene mutations were identified in the ctDNA of the 41 patients analyzed before surgery. ctDNA was detected in 63.4% and 46% of the patient plasma pre‐ and postoperation, respectively. The preoperative ctDNA positivity rate was significantly lower in the nonrecurrence group than in the recurrence group. With a median follow‐up of 17.7 months, nine patients (22%) experienced tumor recurrence. ctDNA positivity at two time‐points was associated with significantly shorter recurrence‐free survival (RFS). Tumors with NRAS, NEF2L2, and MET mutations had significantly shorter times to recurrence than those without mutations and showed high recurrence prediction performance by machine learning. Multivariate analyses showed that the median variant allele frequency (VAF) of mutations in preoperative ctDNA was a strong independent predictor of RFS. ctDNA is a real‐time monitoring indicator that can accurately reflect tumor burden. The median VAF of baseline ctDNA is a strong independent predictor of RFS in individuals with HCC.
format Online
Article
Text
id pubmed-8763657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87636572022-01-21 Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study Zhu, Gui‐Qi Liu, Wei‐Ren Tang, Zheng Qu, Wei‐Feng Fang, Yuan Jiang, Xi‐Fei Song, Shu‐Shu Wang, Han Tao, Chen‐Yang Zhou, Pei‐Yun Huang, Run Gao, Jun Sun, Hai‐Xiang Ding, Zhen‐Bin Peng, Yuan‐Fei Dai, Zhi Zhou, Jian Fan, Jia Shi, Ying‐Hong Mol Oncol Research Articles We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC). Plasma‐free DNA, germline DNA, and tissue DNA were isolated from 41 patients with HCC. Serial ctDNAs were analyzed by next‐generation sequencing before and after operation. Whole‐exome sequencing was used to detect the DNA of HCC and adjacent tissues. In total, 47 gene mutations were identified in the ctDNA of the 41 patients analyzed before surgery. ctDNA was detected in 63.4% and 46% of the patient plasma pre‐ and postoperation, respectively. The preoperative ctDNA positivity rate was significantly lower in the nonrecurrence group than in the recurrence group. With a median follow‐up of 17.7 months, nine patients (22%) experienced tumor recurrence. ctDNA positivity at two time‐points was associated with significantly shorter recurrence‐free survival (RFS). Tumors with NRAS, NEF2L2, and MET mutations had significantly shorter times to recurrence than those without mutations and showed high recurrence prediction performance by machine learning. Multivariate analyses showed that the median variant allele frequency (VAF) of mutations in preoperative ctDNA was a strong independent predictor of RFS. ctDNA is a real‐time monitoring indicator that can accurately reflect tumor burden. The median VAF of baseline ctDNA is a strong independent predictor of RFS in individuals with HCC. John Wiley and Sons Inc. 2021-10-04 2022-01 /pmc/articles/PMC8763657/ /pubmed/34543520 http://dx.doi.org/10.1002/1878-0261.13105 Text en © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Zhu, Gui‐Qi
Liu, Wei‐Ren
Tang, Zheng
Qu, Wei‐Feng
Fang, Yuan
Jiang, Xi‐Fei
Song, Shu‐Shu
Wang, Han
Tao, Chen‐Yang
Zhou, Pei‐Yun
Huang, Run
Gao, Jun
Sun, Hai‐Xiang
Ding, Zhen‐Bin
Peng, Yuan‐Fei
Dai, Zhi
Zhou, Jian
Fan, Jia
Shi, Ying‐Hong
Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
title Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
title_full Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
title_fullStr Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
title_full_unstemmed Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
title_short Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
title_sort serial circulating tumor dna to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763657/
https://www.ncbi.nlm.nih.gov/pubmed/34543520
http://dx.doi.org/10.1002/1878-0261.13105
work_keys_str_mv AT zhuguiqi serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT liuweiren serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT tangzheng serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT quweifeng serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT fangyuan serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT jiangxifei serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT songshushu serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT wanghan serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT taochenyang serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT zhoupeiyun serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT huangrun serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT gaojun serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT sunhaixiang serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT dingzhenbin serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT pengyuanfei serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT daizhi serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT zhoujian serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT fanjia serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy
AT shiyinghong serialcirculatingtumordnatopredictearlyrecurrenceinpatientswithhepatocellularcarcinomaaprospectivestudy